Skip to main content

GlaxoSmithKline-gsk-logo

An international drug giant and a La Jolla venture capital firm are expanding their partnership to create local biotech companies, a sign that the partnership — and the promise of new disease therapies — is progressing.

GSK will increase potential milestone payments to Avalon Ventures from $40 million to $50 million for each biotech formed. In return, the venture capital firm is assuming more risk by increasing its proportion of funding by an undisclosed amount.

{iframe}http://www.sandiegouniontribune.com/news/2015/nov/09/gsk-avalon-expand-iron-horse-als/{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.